Sophie Leboulleux

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study”.

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

The Lancet Diabetes & Endocrinology(2021)10.1016/s2213-8587(21)00120-0

N/A

5.1DataRank · unranked

354 citations

Mimi I. Hu, Lori J. Wirth, Martin Schüler, Aaron S. Mansfield, Giuseppe Curigliano +20 more

Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement

The Lancet Diabetes & Endocrinology(2025)10.1016/s2213-8587(25)00064-6

N/A

0DataRank · unranked

28 citations

Laura Boucai, Naifa L. Busaidy, Cosimo Durante, James A. Fagin, Sasan Fazeli +12 more